Blab Business
Zelluna ASA Registers Share Capital Increase, Issuing 446,752 Shares to Inven2 AS
Zelluna ASA (OSE: ZLNA), a Norwegian biotechnology firm developing allogeneic T‑cell receptor‑based natural killer (TCR‑NK) cell therapies for solid tumours, announced on 10 August 2026 that its share capital had been increased to NOK 29 860 511. The increase involved the issuance of 446 752 new shares to Inven2 AS, a venture‑capital company owned by the University of Oslo and Oslo University Hospital.
The share capital change was made pursuant to a board resolution dated 4 August 2026, which followed an authorisation granted by Zelluna’s Annual General Meeting on 23 April 2026. The board had been empowered to raise up to NOK 800 000 in share capital to settle amounts owed to Inven2 under an option and license agreement. The company settled the share contribution by set‑off against an aggregate debt of EUR 791 666.70 (NOK 8 834 604.54) that Zelluna owed to Inven2. The transaction was registered with the Norwegian Register of Business Enterprises on the same day, bringing the company’s share capital to 29 860 511 shares, each with a nominal value of NOK 1.00.
Zelluna’s platform combines the innate cytotoxic activity of natural killer cells with tumour‑specific targeting by engineered T‑cell receptors. Its lead candidate, ZI‑MA4‑1 (also known as ZIMA‑101), is the first MAGE‑A4‑targeting TCR‑NK therapy in clinical development. The company’s clinical programme has progressed to the first‑in‑human trial stage, with regulatory filings in the United Kingdom and the United Kingdom’s Medicines and Healthcare products Regulatory Agency.
Inven2 AS, the recipient of the new shares, is a venture‑capital firm headquartered in Oslo that focuses on health‑tech and biotechnology. The company’s investment activities are supported by the University of Oslo and Oslo University Hospital. By receiving shares in Zelluna, Inven2 strengthens its equity position in a company that has secured a 10.79 % stake in Zelluna’s outstanding shares following the transaction.
The share capital increase is part of Zelluna’s broader strategy to fund ongoing clinical development and scale its manufacturing capabilities. The company has previously raised capital through private placements and retail offerings, and the recent increase aligns with its plan to secure additional financing for the next phases of its clinical programme.
According to the company’s announcement, the share issuance was fully settled by set‑off, meaning no cash outlay was required from Zelluna’s balance sheet. The transaction also reflects the contractual relationship between Zelluna and Inven2, which includes an option and license agreement that governs the transfer of intellectual property and technology rights.
The Norwegian Securities Trading Act requires disclosure of such share capital changes, and Zelluna complied by publishing the information on the Oslo Stock Exchange and the Norwegian Register of Business Enterprises. The company’s website (www.zelluna.com) provides further details and contact information for its CEO, Namir Hassan, and CFO, Geir Christian Melen.
For investors, the share capital increase does not alter Zelluna’s market capitalization directly, as the shares were issued to settle a debt rather than to raise new equity. However, the transaction increases the number of shares outstanding, which could affect earnings per share calculations in future financial statements.
Zelluna remains listed on the Oslo Stock Exchange under the ticker ZLNA. The company’s next public disclosure will likely include its upcoming earnings report and any updates on regulatory approvals for ZI‑MA4‑1. The share capital increase is a routine corporate action that aligns with the company’s ongoing development plans and its partnership with Inven2.
In summary, Zelluna ASA has increased its share capital to NOK 29 860 511 by issuing 446 752 shares to Inven2 AS, settling a debt of NOK 8 834 604.54 through set‑off. The move follows an AGM‑authorised board resolution and is registered with the Norwegian Register of Business Enterprises. The transaction strengthens Zelluna’s financial position and reinforces its collaboration with Inven2 as it advances its TCR‑NK cell therapy platform.
The share capital change was made pursuant to a board resolution dated 4 August 2026, which followed an authorisation granted by Zelluna’s Annual General Meeting on 23 April 2026. The board had been empowered to raise up to NOK 800 000 in share capital to settle amounts owed to Inven2 under an option and license agreement. The company settled the share contribution by set‑off against an aggregate debt of EUR 791 666.70 (NOK 8 834 604.54) that Zelluna owed to Inven2. The transaction was registered with the Norwegian Register of Business Enterprises on the same day, bringing the company’s share capital to 29 860 511 shares, each with a nominal value of NOK 1.00.
Zelluna’s platform combines the innate cytotoxic activity of natural killer cells with tumour‑specific targeting by engineered T‑cell receptors. Its lead candidate, ZI‑MA4‑1 (also known as ZIMA‑101), is the first MAGE‑A4‑targeting TCR‑NK therapy in clinical development. The company’s clinical programme has progressed to the first‑in‑human trial stage, with regulatory filings in the United Kingdom and the United Kingdom’s Medicines and Healthcare products Regulatory Agency.
Inven2 AS, the recipient of the new shares, is a venture‑capital firm headquartered in Oslo that focuses on health‑tech and biotechnology. The company’s investment activities are supported by the University of Oslo and Oslo University Hospital. By receiving shares in Zelluna, Inven2 strengthens its equity position in a company that has secured a 10.79 % stake in Zelluna’s outstanding shares following the transaction.
The share capital increase is part of Zelluna’s broader strategy to fund ongoing clinical development and scale its manufacturing capabilities. The company has previously raised capital through private placements and retail offerings, and the recent increase aligns with its plan to secure additional financing for the next phases of its clinical programme.
According to the company’s announcement, the share issuance was fully settled by set‑off, meaning no cash outlay was required from Zelluna’s balance sheet. The transaction also reflects the contractual relationship between Zelluna and Inven2, which includes an option and license agreement that governs the transfer of intellectual property and technology rights.
The Norwegian Securities Trading Act requires disclosure of such share capital changes, and Zelluna complied by publishing the information on the Oslo Stock Exchange and the Norwegian Register of Business Enterprises. The company’s website (www.zelluna.com) provides further details and contact information for its CEO, Namir Hassan, and CFO, Geir Christian Melen.
For investors, the share capital increase does not alter Zelluna’s market capitalization directly, as the shares were issued to settle a debt rather than to raise new equity. However, the transaction increases the number of shares outstanding, which could affect earnings per share calculations in future financial statements.
Zelluna remains listed on the Oslo Stock Exchange under the ticker ZLNA. The company’s next public disclosure will likely include its upcoming earnings report and any updates on regulatory approvals for ZI‑MA4‑1. The share capital increase is a routine corporate action that aligns with the company’s ongoing development plans and its partnership with Inven2.
In summary, Zelluna ASA has increased its share capital to NOK 29 860 511 by issuing 446 752 shares to Inven2 AS, settling a debt of NOK 8 834 604.54 through set‑off. The move follows an AGM‑authorised board resolution and is registered with the Norwegian Register of Business Enterprises. The transaction strengthens Zelluna’s financial position and reinforces its collaboration with Inven2 as it advances its TCR‑NK cell therapy platform.
